We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Selvita Signs a Drug Discovery Services Contract with Rottapharm Madaus"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Rottapharm Madaus and Selvita announced signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.

“We are delighted to start an FTE-based collaboration with Selvita. We are keen to take advantage of  Selvita’s know-how to support the progression of our drug discovery pipeline"  – said Luigi Stasi, Rottapharm’s Director of Medicinal Chemistry Department. "We are looking forward to a very fruitful and effective cooperation."

"We are very pleased and honored that we can cooperate with such a prestigious multinational pharmaceutical company as Rottapharm Madaus" – said Pawel Przewiezlikowski, Selvita’s CEO.

"This project is an immense chance for Selvita to show the great potential of our Computational Chemistry and Chemistry Departments. Working for Rottapharm Madaus on this project will enable us to take a full advantage of our highly skilled scientists and new facilities, and I truly believe we can deliver exactly what Rottapharm Madaus needs. I’m looking forward to this cooperation very much,” he added.